A randomised trial of the effects of SGLT2 inhibition versus metformin on decline in renal function when used as first line therapy in type 2 diabetes

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2006893

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Type 2 diabetes affects 5 in 100 Australians with many going on to develop serious heart and kidney complications. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new type of medicine that may provide benefit when used early in diabetes, but that are currently only used once complications have developed. This study will test the value of SGLT2 inhibitor treatment for kidney protection in Australians with newly diagnosed type 2 diabetes.

Funded Activity Details

Start Date: 01-01-2021

End Date: End date not available

Funding Scheme: Clinical Trials and Cohort Studies Grants

Funding Amount: $3,815,692.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

blood pressure | clinical trial | diabetes | diabetic nephropathy

Related Links